share_log

艾美疫苗：截至2023年12月31日止年度全年業績公告

AIM VACCINE: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023

香港交易所 ·  Mar 27 20:02
Summary by Moomoo AI
艾美疫苗(06660.HK)公布截至2023年12月31日止年度全年業績，收入下降6.1%至人民幣1,187,468千元，毛利下降12.3%至人民幣901,016千元。公司母公司擁有人應佔虧損大幅增加至人民幣1,301,005千元，較去年同期增加307.1%。研發支出增加至人民幣636,401千元，上升27.2%。公司於年內完成多項臨床試驗，包括5個III期臨床收尾階段的疫苗產品，並為上市前準備。公司疫苗產品覆蓋免疫規劃疫苗和非免疫規劃疫苗，並在全球範圍內進行註冊和銷售。公司繼續推進mRNA技術平台疫苗的研發，並計劃未來擴大疫苗接種至全人群。公司疫苗產品在國內外市場的註冊和銷售工作正在進行中，並積極推動疫苗的世界衛生組織預認證。公司的疫苗產品已在東南亞、非洲、南美、中東等地區開始註冊工作，狂犬疫苗已獲得巴基斯坦等國的註冊許可。
艾美疫苗(06660.HK)公布截至2023年12月31日止年度全年業績，收入下降6.1%至人民幣1,187,468千元，毛利下降12.3%至人民幣901,016千元。公司母公司擁有人應佔虧損大幅增加至人民幣1,301,005千元，較去年同期增加307.1%。研發支出增加至人民幣636,401千元，上升27.2%。公司於年內完成多項臨床試驗，包括5個III期臨床收尾階段的疫苗產品，並為上市前準備。公司疫苗產品覆蓋免疫規劃疫苗和非免疫規劃疫苗，並在全球範圍內進行註冊和銷售。公司繼續推進mRNA技術平台疫苗的研發，並計劃未來擴大疫苗接種至全人群。公司疫苗產品在國內外市場的註冊和銷售工作正在進行中，並積極推動疫苗的世界衛生組織預認證。公司的疫苗產品已在東南亞、非洲、南美、中東等地區開始註冊工作，狂犬疫苗已獲得巴基斯坦等國的註冊許可。
AMIE VACCINES (06660.HK) ANNOUNCED ITS ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023, WITH REVENUE DOWN 6.1% TO RMB1,187,468 THOUSAND AND GROSS PROFIT DOWN 12.3% TO RMB901,016K. The owners' loss of the parent company increased significantly to RMB 1,301,005 thousand, an increase of 307.1% from the same period last year. R&D expenditure increased to RMB636,401 thousand, up 27.2%. During the year, the Company completed several clinical trials, including 5 Phase III clinical end-of-life vaccine products, and prepared them for the market. THE COMPANY'S VACCINE PRODUCTS COVER IMMUNOPLANNED AND NON-IMMUNOPLANNED VACCINES AND ARE REGISTERED AND SOLD GLOBALLY. The company continues to advance the development of mRNA technology platform vaccines and plans to expand vaccination coverage to the general population in the future. Registration and sales of...Show More
AMIE VACCINES (06660.HK) ANNOUNCED ITS ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023, WITH REVENUE DOWN 6.1% TO RMB1,187,468 THOUSAND AND GROSS PROFIT DOWN 12.3% TO RMB901,016K. The owners' loss of the parent company increased significantly to RMB 1,301,005 thousand, an increase of 307.1% from the same period last year. R&D expenditure increased to RMB636,401 thousand, up 27.2%. During the year, the Company completed several clinical trials, including 5 Phase III clinical end-of-life vaccine products, and prepared them for the market. THE COMPANY'S VACCINE PRODUCTS COVER IMMUNOPLANNED AND NON-IMMUNOPLANNED VACCINES AND ARE REGISTERED AND SOLD GLOBALLY. The company continues to advance the development of mRNA technology platform vaccines and plans to expand vaccination coverage to the general population in the future. Registration and sales of the company's vaccine products in the domestic and foreign markets are underway and are actively promoting the pre-certification of the vaccine by the World Health Organization. The company's vaccine products have been registered in Southeast Asia, Africa, South America, the Middle East and other regions, and rabies vaccines have been licensed in countries such as Pakistan.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more